Document is current

Article History

Accepted: 16 May 2025

First Online: 20 June 2025

Declarations

:

: No external funding was used in the preparation of this manuscript.

: Karissa Britten has no conflicts of interest that might be relevant to the contents of this manuscript. Nicholas McAndrew has acted in a consulting capacity for—Novartis, Daiichi Sankyo, Genomic Health, Mersana, Gilead, and Astra Zenica and has received grants to their institution from Novartis, Daiichi Sankyo, Dizal, Seattle Genetics/Pfizer, Mersana, Loxo, Arvinas, and Eisai. Aditya Bardia has acted in a consulting capacity for Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Alyssum, and Eli Lilly and received grants to their institution from Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Daiichi Pharma/Astra Zeneca, and Eli Lilly.

: Not applicable.

: Not applicable.

: Not applicable.

: No datasets were generated or analyzed during the current study.

: Not applicable.

: Writing, review, and editing: KB, AB, NM.